(Updates)

** Shares of EyePoint Pharmaceuticals slide 8.5% to $11.09 after the bell

** EYPT

unveils

public offering of $100 mln worth of shares

** J.P. Morgan, Citigroup and Guggenheim Securities are the joint book running managers for the offering

** EYPT stock closed up 27.6% at $12.12 on Monday

** Co has 53.5 mln outstanding shares, giving it a $648.6 mln market capitalization - LSEG data

** Earlier in the day, EYPT said its drug, Duravyu, showed an improvement in how well patients can see objects at a distance in a mid-stage trial testing it in diabetic macular edema $(DME.AU)$

** EYPT plans on using the proceeds to advance the development of Duravyu as well as support its earlier stage pipeline development initiatives

** DME is an eye condition that causes blurry vision in people with diabetes

** EYPT expects to report the full topline results in Q1 2025

** As of last close, EYPT stock down 47.6% YTD

(Reporting by Puyaan Singh and Arasu Kannagi Basil in Bengaluru)

((Puyaan.Singh@thomsonreuters.com;))